Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: panbela.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2021 | $10.00 | Buy | Roth Capital |
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)
S-1/A - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
424B3 - Panbela Therapeutics, Inc. (0001029125) (Filer)
10-Q - Panbela Therapeutics, Inc. (0001029125) (Filer)
8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)
Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00
Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third independent safety review: DSMB recommended continuation without modification.Completed Oral Presentation at Digestive Disease Week (DDW): Evaluation of the Safety and Efficacy of Eflornithine (Difluoro
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center. "Gastric adenocarcinoma is the fifth leading global cause of cancer mortality and leading infection-associated cancer. In the U.S., gastric adenocarcinoma represents a major cancer disparity, with incidence rates 2-3 times or more greater in all non-white populations. Pa
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. Q1 2024 and recent Highlights: Clinical Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with standard-of-care for metastatic pancreatic ductal adenocarcinoma (mPDAC). The analysis is now expected in Q1 2025 due to a l
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled "EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION". These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi. The product was developed in collaboration with Sanofi, an innovative global healthcare company. Flynpovi is Panbela's lead investigational product for the treatment of patien
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center. Details of the presentation are as follows: Oral Presentation Title: Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with
MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025. This delay in the projected date for analysis comes as a result of the trial's current event rate, which is lower than initially anticipated, indicating that patients have lived longer than expected. The ASPIRE trial, which is evaluating the efficacy and safety of Panbela's lead product candidate, ivospemin (SBP-101), in combination with gemc
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA)("Panbela"), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), which took place April 10, 2024. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine. "Ivospemin, reduces the viability of human ovarian adenocarcinoma cell lines regardless of their platinum sensitivity and we found that the co
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 195310Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/49978 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 49978Webcast Replay:
MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2023 and Recent Highlights Collaborations Divestiture of assets within eflornithine (DFMO) pediatric neuroblastoma program to US WorldMeds® for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. Clinical The independent Data Safety Monitor
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: November 9, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 100225International: 973-528-0011; Code: 100225Webcast: https://www.webcaster4.com/Webcast/Page
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: Thursday, August 10, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 681215International: 973-528-0011; Code: 681215Webcast: https://www.webcaster4.com/Webca
MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: Thursday, May 04, 2023 Time: 4:30 PM Eastern Time Participant Numbers: Toll Free: 888-506-0062; Code: 130038 International: 973-528-0011; Code: 130038 Webcast: https://www.webcaster4.com/W
MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 16, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2022. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 116790Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/47782 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 47782Webca
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November 10, 2022Time: 4:30 PM Eastern Time Participant Numbers:Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 598956 Webcast Link: h
MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2022. Management is hosting an earnings conference call today at 4:30 p.m. ET. The second quarter was marked by meaningful progress. Q2 and Recent Highlights: First Patient Enrolled in its Aspire Trial.Received approval from the Australian Human Research Ethics Committee (HREC) to expand the company's global clinical trial to Australia.Closed on the acquisition of Cancer Prevention Phar
HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.
HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.48) by 54.05 percent.
HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.
Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.
Panbela Therapeutics (OTC:PBLA) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:10 PM. Here's what investors need to know about the announcement. Earnings Panbela Therapeutics missed estimated earnings by -171.0%, reporting an EPS of $-65.9 versus an estimate of $-24.34. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.36 which was followed by a 3.0% increase in the share price the next day. To track all earnings releases for Panbela Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate of $(24.34) by 170.75 percent.
Panbela Therapeutics (NASDAQ:PBLA) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement. Analysts estimate that Panbela Therapeutics will report an earnings per share (EPS) of $-24.34. Panbela Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.36, which was followed
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. ProSomnus, Inc. (NASDAQ:OSA) On Feb. 22, ProSomnus reported successful pilot study validation of next generation remote patient m